evipedia.ai
← Back

Periodic Phlebotomy for Health & Longevity

Created on 10/23/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Periodic phlebotomy is the planned, repeated removal of about half a liter of blood, by donation or prescription, to lower the body's iron stores. It is the standard treatment for inherited iron overload, but for health-focused adults without iron excess its value for longevity remains unproven. Frequent removal reliably drains iron, can bring fatigue and restless legs, sometimes causes fainting, and distorts a common blood sugar test. (Full Review)

Protocol

Standard unit
About 500 mL
Of whole blood per session; smaller draws of 250–500 mL in the metabolic syndrome trial
Blood-service approach
At least 8 weeks
Between whole-blood donations under US rules; WHO advises at least 12 weeks for men and 16 for women
Trial approach (FeAST)
Ferritin 20–100 ng/mL
Range later proposed by its investigators; defined volumes removed every 6 months
Time to effect
Ferritin
Within weeks
Falls after each unit
Blood pressure
6 weeks
When the blood-pressure trial measured its effect
Long-term disease effects
Years
None established in healthy people

Benefits

Contraindications
  • Hemoglobin below 13.0 g/dL in men (hematocrit below 39%) or below 12.5 g/dL in women (below 38%)
  • Systolic blood pressure above 180 or below 90 mmHg, or diastolic above 100 or below 50 mmHg, unless a physician clears the donor
  • Pulse irregular or outside 50–100 beats per minute without physician clearance, or body weight below 50 kg
  • Pregnancy or within 6 weeks of pregnancy
  • Documented anemia, recent blood loss, bleeding disorders, history of blood-pressure drop on standing or kidney function below an estimated filtration rate of 60 mL/min
  • Unstable coronary disease, decompensated heart failure or severe aortic valve narrowing
    •
Key Interactions
  • Oral iron supplements (ferrous sulfate): Monitor. Restores the iron being removed
  • Proton pump inhibitors (omeprazole): Monitor. Adds to iron-depletion risk
  • Testosterone and SGLT2 inhibitors (empagliflozin): Caution. Both raise hematocrit
  • Blood pressure drugs (amlodipine) and diuretics (hydrochlorothiazide): Caution (theoretical). Lightheadedness on standing and fainting
  • Anticoagulants and antiplatelet drugs (warfarin, clopidogrel): Caution (theoretical). Larger bruising or prolonged needle-site bleeding
  • Over-the-counter pain relievers (aspirin): Caution (theoretical). Possible extra needle-site bleeding
  • Vitamin C supplements (ascorbic acid): Monitor. Slightly counteracts iron removal
  • Black tea and polyphenol supplements (green tea extract): Monitor (additive). Raises depletion risk if combined
  • Other interventions (sauna): Caution (theoretical). Adds volume loss and fainting risk on the day of phlebotomy
    •

Risk & Side Effects

  • High: Iron depletion and low hemoglobin, fatigue and restless legs
    •
  • Medium: Vasovagal reactions and needle-site complications, weight gain, reduced aerobic exercise capacity
    •
  • Low: Falsely low glycated hemoglobin readings
    •
  • Speculative: Selection of mutant blood stem cells, heart strain from reduced blood supply in heart disease
    •

Monitoring

Marker Target Why
Hemoglobin Men at least 13.0 g/dL, women at least 12.5 g/dL Safety check; low value stops the session
Ferritin 20–100 ng/mL (proposed) Expected to change; low value pauses sessions
Transferrin saturation 20–50% (proposed) Expected to change; safety check below 20%
Hematocrit Below 45% in polycythemia vera Expected to change; safety check for anemia
MCV 80–100 fL Falling value signals iron-limited red-cell production
Blood pressure Below 120/80 mmHg Expected to change
Fasting glucose 70–99 mg/dL Preferred glycemic marker during phlebotomy
HbA1c 4.0–5.6% Expected to change; reads falsely low after donation
ALT 7–56 U/L Expected to change in fatty liver
HFE genotype Not specified in the ER Result changes use
hs-CRP Not specified in the ER Inflammation raises ferritin

Cadence: Baseline before the first session; hemoglobin at every session; ferritin every 2–3 sessions or every 3–6 months; blood pressure, fasting glucose and liver enzymes every 6–12 months; HFE genotype once, where ferritin or saturation is high

Qualitative Assessment

  • Energy and fatigue level in the days and weeks after each session
  • Exercise tolerance and breathlessness on exertion
  • Restless legs or nighttime leg discomfort
  • Lightheadedness on standing
  • Sleep quality
  • Cold intolerance, brittle nails or hair shedding as signs of iron deficiency
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.